Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database

Our study highlights the importance of post-market surveillance for monitoring the safety of mepolizumab, which revealed significant AE signals, particularly for respiratory diseases, infections, and immune system complications. The association with opportunistic infections, including COVID-19, highlights the need for vigilant surveillance and further research.